









Markets
/
Stocks
/
nasdaq-nmtc
/

NeuroOne Medical Technologies Corp

NMTC

0.780USD

+0.045+6.16%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

39.02MMarket Cap

LossP/E TTM



NeuroOne Medical Technologies Corp

0.780

+0.045+6.16%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of NeuroOne Medical Technologies Corp

Currency: USD Updated: 2026-02-06

Key Insights

NeuroOne Medical Technologies Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 79 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 2.30.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

NeuroOne Medical Technologies Corp's Score

Industry at a Glance

Industry Ranking

79 / 205

Overall Ranking

214 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

NeuroOne Medical Technologies Corp Highlights

StrengthsRisks

NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 250.82% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 12.10M.

Undervalued

The company’s latest PE is -8.69, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 16.80M shares, decreasing 3.74% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 692.60K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.35.

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

2.300

Target Price

+186.71%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of NeuroOne Medical Technologies Corp is 8.22, ranking 53 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.74M, representing a year-over-year increase of 906.64%, while its net profit experienced a year-over-year increase of 51.67%.

Score

Industry at a Glance

Previous score

8.22

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

5.58

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

NeuroOne Medical Technologies Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of NeuroOne Medical Technologies Corp is 7.08, ranking 128 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -8.69, which is -86.63% below the recent high of -1.16 and -25.66% above the recent low of -10.92.

Score

Industry at a Glance

Previous score

7.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 79/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of NeuroOne Medical Technologies Corp is 9.00, ranking 6 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 2.23, with a high of 3.00 and a low of 1.45.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

2.300

Target Price

+186.71%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

NeuroOne Medical Technologies Corp

NMTC

Intuitive Surgical Inc

ISRG

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of NeuroOne Medical Technologies Corp is 6.71, ranking 99 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 0.91 and the support level at 0.68, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.19

Change

0.52

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.041

Neutral

RSI(14)

43.734

Neutral

STOCH(KDJ)(9,3,3)

20.512

Neutral

ATR(14)

0.065

Low Volatility

CCI(14)

-176.979

Sell

Williams %R

69.647

Sell

TRIX(12,20)

0.166

Sell

StochRSI(14)

44.064

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

0.802

Sell

MA10

0.846

Sell

MA20

0.866

Sell

MA50

0.782

Sell

MA100

0.804

Sell

MA200

0.761

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of NeuroOne Medical Technologies Corp is 3.00, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 33.31%, representing a quarter-over-quarter decrease of 2.91%. The largest institutional shareholder is The Vanguard, holding a total of 1.58M shares, representing 3.13% of shares outstanding, with 11.57% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Merchant Adventure Fund LP

4.20M

+236.00%

Bleichroeder LP

4.00M

Sio Capital Management, LLC

2.36M

-33.01%

Bard Associates Inc.

1.85M

-0.19%

The Vanguard Group, Inc.

Star Investors

1.58M

+31.24%

Perkins Capital Management, Inc.

1.47M

-2.13%

AWM Investment Company, Inc.

916.67K

Rosa (David A)

613.29K

-0.40%

Renaissance Technologies LLC

Star Investors

692.60K

+47.71%

Geode Capital Management, L.L.C.

496.83K

+42.43%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of NeuroOne Medical Technologies Corp is 2.21, ranking 161 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.